Other
177Lu-PSMA
177Lu-PSMA is an intervention with 5 clinical trials. Currently 3 active trials ongoing. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
OTHER
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
3(60%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
2
40%
Ph phase_2
2
40%
Phase Distribution
2
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
2(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
3
trials recruiting
Total Trials
5
all time
Status Distribution
Active(3)
Completed(2)
Detailed Status
Completed2
Recruiting2
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
3
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (50.0%)
Phase 22 (50.0%)
Trials by Status
completed240%
active_not_recruiting120%
recruiting240%
Recent Activity
3 active trials
Showing 5 of 5
recruitingphase_2
Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy
NCT05560659
recruiting
ProsTIC Registry of Men Treated With PSMA Theranostics
NCT04769817
active_not_recruitingphase_1
177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer
NCT03874884
completedphase_2
Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC)
NCT03454750
completedphase_1
PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr)
NCT03658447
Clinical Trials (5)
Showing 5 of 5 trials
NCT05560659Phase 2
Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy
NCT04769817
ProsTIC Registry of Men Treated With PSMA Theranostics
NCT03874884Phase 1
177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer
NCT03454750Phase 2
Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC)
NCT03658447Phase 1
PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr)
All 5 trials loaded
Drug Details
- Intervention Type
- OTHER
- Total Trials
- 5